Infographics
-
Comparison Of Selling vs. Manufacturing Biosimilars
6/18/2018
In Q42017, ISR surveyed 177 professionals from biopharmaceutical sponsors to ask about their companies’ current stances on selling and on manufacturing biosimilars.
-
Benefits Of Using Preferred Providers For Clinical Development Outsourcing
5/22/2018
Results from a Q1 2018 ISR survey of 117 outsourcers at biopharmaceutical sponsors regarding the use and performance of a variety of clinical development outsourcing models.
-
Outsourced Manufacturing: Comparing Large Vs. Small Molecule
5/22/2018
Results from a Q42017 ISR survey of 177 biopharmaceutical sponsors asking how the proportion of outsourced manufacturing for large molecule products compare to that of small molecule products.
-
Outsourcers’ CMO Preferences
In Q4, 2019, ISR asked 676 buyers of outsourced manufacturing services about which types of CMOs their organization prefers, large, global CMOs with broad capabilities or Small, niche CMOs with highly specialized capabilities. Respondents’ preference leans towards the big guys. 44% agree-strongly agree that their organization prefers large, global CMOs as compared to 28% who indicate their organization prefers smaller, niche CMOs with specialized capabilities.
-
Use Of Preferred Providers Among Biologic Outsourcers
ISR surveyed outsourcers of biologic API and outsourcers of biologic drug product to ask whether their company uses a preferred providers list for outsourced manufacturing. The majority of respondents do, for both large molecule API (59%) and large molecule drug product manufacturing (61%).
-
Improving Manufacturing Outsourcing Relationships
In Q4, 2018, ISR asked 100 sponsors who outsource manufacturing about several different scenarios that could potentially improve outsourcing relationships. The data below show how each of the scenarios panned out. A key common element across the most likely scenarios—communication.
-
Customer Loyalty In Small Molecule Drug Product Manufacturing
In Q42020, ISR surveyed 123 sponsors who outsource small molecule drug product to gain insight into customer loyalty. CMO loyalty is computed as an index that consists of overall satisfaction, willingness to recommend, and the likelihood of using the contract manufacturer again.
-
Outsourcing Practices And CMO Opinions
60 percent of outsourced manufacturing buyers say a focus on innovative treatments impact their outsourcing practices. Half prefer large global CMOs, 40 percent prefer CMOs with specialized capabilities.